990 related articles for article (PubMed ID: 30683154)
1. Targeting the tumor stroma with an oncolytic adenovirus secreting a fibroblast activation protein-targeted bispecific T-cell engager.
de Sostoa J; Fajardo CA; Moreno R; Ramos MD; Farrera-Sal M; Alemany R
J Immunother Cancer; 2019 Jan; 7(1):19. PubMed ID: 30683154
[TBL] [Abstract][Full Text] [Related]
2. Oncolytic Adenoviral Delivery of an EGFR-Targeting T-cell Engager Improves Antitumor Efficacy.
Fajardo CA; Guedan S; Rojas LA; Moreno R; Arias-Badia M; de Sostoa J; June CH; Alemany R
Cancer Res; 2017 Apr; 77(8):2052-2063. PubMed ID: 28143835
[TBL] [Abstract][Full Text] [Related]
3. Improving CART-Cell Therapy of Solid Tumors with Oncolytic Virus-Driven Production of a Bispecific T-cell Engager.
Wing A; Fajardo CA; Posey AD; Shaw C; Da T; Young RM; Alemany R; June CH; Guedan S
Cancer Immunol Res; 2018 May; 6(5):605-616. PubMed ID: 29588319
[TBL] [Abstract][Full Text] [Related]
4. An Oncolytic Virus Expressing a T-cell Engager Simultaneously Targets Cancer and Immunosuppressive Stromal Cells.
Freedman JD; Duffy MR; Lei-Rossmann J; Muntzer A; Scott EM; Hagel J; Campo L; Bryant RJ; Verrill C; Lambert A; Miller P; Champion BR; Seymour LW; Fisher KD
Cancer Res; 2018 Dec; 78(24):6852-6865. PubMed ID: 30449733
[TBL] [Abstract][Full Text] [Related]
5. Oncolytic herpesvirus expressing PD-L1 BiTE for cancer therapy: exploiting tumor immune suppression as an opportunity for targeted immunotherapy.
Khalique H; Baugh R; Dyer A; Scott EM; Frost S; Larkin S; Lei-Rossmann J; Seymour LW
J Immunother Cancer; 2021 Mar; 9(4):. PubMed ID: 33820820
[TBL] [Abstract][Full Text] [Related]
6. Bispecific single-chain diabody-immunoliposomes targeting endoglin (CD105) and fibroblast activation protein (FAP) simultaneously.
Rabenhold M; Steiniger F; Fahr A; Kontermann RE; Rüger R
J Control Release; 2015 Mar; 201():56-67. PubMed ID: 25617725
[TBL] [Abstract][Full Text] [Related]
7. Blockade of fibroblast activation protein in combination with radiation treatment in murine models of pancreatic adenocarcinoma.
Gunderson AJ; Yamazaki T; McCarty K; Phillips M; Alice A; Bambina S; Zebertavage L; Friedman D; Cottam B; Newell P; Gough MJ; Crittenden MR; Van der Veken P; Young KH
PLoS One; 2019; 14(2):e0211117. PubMed ID: 30726287
[TBL] [Abstract][Full Text] [Related]
8. Oncolytic adenovirus and gene therapy with EphA2-BiTE for the treatment of pediatric high-grade gliomas.
Arnone CM; Polito VA; Mastronuzzi A; Carai A; Diomedi FC; Antonucci L; Petrilli LL; Vinci M; Ferrari F; Salviato E; Scarsella M; De Stefanis C; Weber G; Quintarelli C; De Angelis B; Brenner MK; Gottschalk S; Hoyos V; Locatelli F; Caruana I; Del Bufalo F
J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 33963009
[TBL] [Abstract][Full Text] [Related]
9. T-cell engager-armed oncolytic vaccinia virus significantly enhances antitumor therapy.
Yu F; Wang X; Guo ZS; Bartlett DL; Gottschalk SM; Song XT
Mol Ther; 2014 Jan; 22(1):102-11. PubMed ID: 24135899
[TBL] [Abstract][Full Text] [Related]
10. Activatable bispecific liposomes bearing fibroblast activation protein directed single chain fragment/Trastuzumab deliver encapsulated cargo into the nuclei of tumor cells and the tumor microenvironment simultaneously.
Tansi FL; Rüger R; Böhm C; Steiniger F; Kontermann RE; Teichgraeber UK; Fahr A; Hilger I
Acta Biomater; 2017 May; 54():281-293. PubMed ID: 28347861
[TBL] [Abstract][Full Text] [Related]
11. Oncolytic adenovirus expressing bispecific antibody targets T-cell cytotoxicity in cancer biopsies.
Freedman JD; Hagel J; Scott EM; Psallidas I; Gupta A; Spiers L; Miller P; Kanellakis N; Ashfield R; Fisher KD; Duffy MR; Seymour LW
EMBO Mol Med; 2017 Aug; 9(8):1067-1087. PubMed ID: 28634161
[TBL] [Abstract][Full Text] [Related]
12. Oncolytic adenovirus with MUC16-BiTE shows enhanced antitumor immune response by reversing the tumor microenvironment in PDX model of ovarian cancer.
Wang Q; Ma X; Wu H; Zhao C; Chen J; Li R; Yan S; Li Y; Zhang Q; Song K; Yuan C; Kong B
Oncoimmunology; 2022; 11(1):2096362. PubMed ID: 35800156
[TBL] [Abstract][Full Text] [Related]
13. Oncolytic Adenovirus Armed with BiTE, Cytokine, and Checkpoint Inhibitor Enables CAR T Cells to Control the Growth of Heterogeneous Tumors.
Porter CE; Rosewell Shaw A; Jung Y; Yip T; Castro PD; Sandulache VC; Sikora A; Gottschalk S; Ittman MM; Brenner MK; Suzuki M
Mol Ther; 2020 May; 28(5):1251-1262. PubMed ID: 32145203
[TBL] [Abstract][Full Text] [Related]
14. Antitumor effects of chimeric receptor engineered human T cells directed to tumor stroma.
Kakarla S; Chow KK; Mata M; Shaffer DR; Song XT; Wu MF; Liu H; Wang LL; Rowley DR; Pfizenmaier K; Gottschalk S
Mol Ther; 2013 Aug; 21(8):1611-20. PubMed ID: 23732988
[TBL] [Abstract][Full Text] [Related]
15. Characterization and oncolytic virus targeting of FAP-expressing tumor-associated pericytes in glioblastoma.
Li M; Li G; Kiyokawa J; Tirmizi Z; Richardson LG; Ning J; Das S; Martuza RL; Stemmer-Rachamimov A; Rabkin SD; Wakimoto H
Acta Neuropathol Commun; 2020 Dec; 8(1):221. PubMed ID: 33308315
[TBL] [Abstract][Full Text] [Related]
16. The Efficacy of Oncolytic Adenovirus Is Mediated by T-cell Responses against Virus and Tumor in Syrian Hamster Model.
Li X; Wang P; Li H; Du X; Liu M; Huang Q; Wang Y; Wang S
Clin Cancer Res; 2017 Jan; 23(1):239-249. PubMed ID: 27435398
[TBL] [Abstract][Full Text] [Related]
17. Construction of a bispecific single chain antibody for recruitment of cytotoxic T cells to the tumour stroma associated antigen fibroblast activation protein.
Wüest T; Moosmayer D; Pfizenmaier K
J Biotechnol; 2001 Dec; 92(2):159-68. PubMed ID: 11640985
[TBL] [Abstract][Full Text] [Related]
18. The application of the fibroblast activation protein α-targeted immunotherapy strategy.
Jiang GM; Xu W; Du J; Zhang KS; Zhang QG; Wang XW; Liu ZG; Liu SQ; Xie WY; Liu HF; Liu JS; Wu BP
Oncotarget; 2016 May; 7(22):33472-82. PubMed ID: 26985769
[TBL] [Abstract][Full Text] [Related]
19. Photoimmunotherapy for cancer-associated fibroblasts targeting fibroblast activation protein in human esophageal squamous cell carcinoma.
Watanabe S; Noma K; Ohara T; Kashima H; Sato H; Kato T; Urano S; Katsube R; Hashimoto Y; Tazawa H; Kagawa S; Shirakawa Y; Kobayashi H; Fujiwara T
Cancer Biol Ther; 2019; 20(9):1234-1248. PubMed ID: 31185791
[TBL] [Abstract][Full Text] [Related]
20. A tetravalent bispecific TandAb (CD19/CD3), AFM11, efficiently recruits T cells for the potent lysis of CD19(+) tumor cells.
Reusch U; Duell J; Ellwanger K; Herbrecht C; Knackmuss SH; Fucek I; Eser M; McAleese F; Molkenthin V; Gall FL; Topp M; Little M; Zhukovsky EA
MAbs; 2015; 7(3):584-604. PubMed ID: 25875246
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
